Evidence map›Paper›PMID 39060692›Full record

ArticleAnnals of surgical oncology2024

Quality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC): Cancer Survivors' Perspective Through In-Depth Interviews.

Luis Felipe Falla-Zuniga, Mary Caitlin King, Kathleen Pawlikowski, Andrei Nikiforchin, Felipe Lopez-Ramirez, Philipp Barakat, Sergei Iugai, Carol Nieroda, Vadim Gushchin, Armando Sardi

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Luis Felipe Falla-ZunigaSurgical Oncology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD, USA.
Mary Caitlin KingSurgical Oncology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD, USA.
Kathleen PawlikowskiSurgical Oncology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD, USA.
Andrei NikiforchinSurgical Oncology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD, USA.
Felipe Lopez-RamirezSurgical Oncology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD, USA.
Philipp BarakatSurgical Oncology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD, USA.
Sergei IugaiSurgical Oncology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD, USA.
Carol NierodaSurgical Oncology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD, USA.
Vadim GushchinSurgical Oncology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD, USA.
Armando SardiSurgical Oncology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD, USA. asardi@mdmercy.com.ORCID http://orcid.org/0000-0003-4132-9489

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCRS/HIPEC patients face unique quality of life (QoL) challenges due to advanced disease (peritoneal carcinomatosis), the extent of procedure, and risk for long-term complications. Standard QoL questionnaires are generic, focusing on tumor type and standard treatments, and likely do not capture this select population's full experience, suggesting the need for tailored instruments. We aimed to characterize the QoL challenges faced by CRS/HIPEC cancer survivors and determine whether these were captured by a standard QoL questionnaire. PATIENTS AND

methodsAn anonymous, semi-structured individual interview was conducted with CRS/HIPEC patients addressing their experience at diagnosis, challenges related to CRS/HIPEC, and access to CRS/HIPEC information. Verbatim transcripts were interpreted using thematic analysis. Code and theme identification was inductive. Questions addressing common themes that were not encompassed by a standard QoL questionnaire were developed.

resultsWe interviewed eight patients. Median age was 55 (range 30-71) years and 75% (n = 6) were women. Primary tumor sites included appendix (n = 4), ovarian (n = 3), and peritoneal mesothelioma (n = 1). Median time from CRS/HIPEC was 40.1 (range 3.1-216.3) months. Overall, 133 codes were identified and categorized into 9 themes. The most recurring were physical symptoms after CRS/HIPEC (specifically gastrointestinal symptoms), adjusting to survivorship, mental health, expectations from CRS/HIPEC, and access to care. A total of 22 questions that did not overlap with a standardized QoL questionnaire were developed.

conclusionsThere is an unmet need to understand the unique QoL challenges CRS/HIPEC patients encounter. Patient-centered QoL questionnaires based on CRS/HIPEC patient experiences can capture these unique challenges and help guide future studies and care.

Indexed as

Cancer SurvivorsCytoreduction Surgical ProceduresHyperthermic Intraperitoneal ChemotherapyPeritoneal NeoplasmsQuality of LifeAdultAgedCombined Modality TherapyFemaleFollow-Up StudiesHumansMaleMiddle AgedOvarian NeoplasmsPrognosisSurveys and QuestionnairesAdvanced cancerPatient experiencesPeritoneal surface malignanciesQuality of lifeSurvivorship

Identifiers

PMID39060692

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.